Evidence map›Paper›PMID 29785624›Full record

ArticleNeuroinformatics2019

Longitudinal Neuroimaging Hippocampal Markers for Diagnosing Alzheimer's Disease.

Carlos Platero, Lin Lin, M Carmen Tobar

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Frontiers in oncology · 2021
    Article
  7. Article
  8. Observational
  9. Observational
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carlos PlateroHealth Science Technology Group, Universidad Politécnica de Madrid, Ronda de Valencia 3, 28012, Madrid, Spain. carlos.platero@upm.es.ORCID http://orcid.org/0000-0003-3712-8297
Lin LinUniversidad Politécnica de Madrid, Ronda de Valencia 3, 28012, Madrid, Spain.
M Carmen TobarHealth Science Technology Group, Universidad Politécnica de Madrid, Ronda de Valencia 3, 28012, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hippocampal atrophy measures from magnetic resonance imaging (MRI) are powerful tools for monitoring Alzheimer's disease (AD) progression. In this paper, we introduce a longitudinal image analysis framework based on robust registration and simultaneous hippocampal segmentation and longitudinal marker classification of brain MRI of an arbitrary number of time points. The framework comprises two innovative parts: a longitudinal segmentation and a longitudinal classification step. The results show that both steps of the longitudinal pipeline improved the reliability and the accuracy of the discrimination between clinical groups. We introduce a novel approach to the joint segmentation of the hippocampus across multiple time points; this approach is based on graph cuts of longitudinal MRI scans with constraints on hippocampal atrophy and supported by atlases. Furthermore, we use linear mixed effect (LME) modeling for differential diagnosis between clinical groups. The classifiers are trained from the average residue between the longitudinal marker of the subjects and the LME model. In our experiments, we analyzed MRI-derived longitudinal hippocampal markers from two publicly available datasets (Alzheimer's Disease Neuroimaging Initiative, ADNI and Minimal Interval Resonance Imaging in Alzheimer's Disease, MIRIAD). In test/retest reliability experiments, the proposed method yielded lower volume errors and significantly higher dice overlaps than the cross-sectional approach (volume errors: 1.55% vs 0.8%; dice overlaps: 0.945 vs 0.975). To diagnose AD, the discrimination ability of our proposal gave an area under the receiver operating characteristic (ROC) curve (AUC) [Formula: see text] 0.947 for the control vs AD, AUC [Formula: see text] 0.720 for mild cognitive impairment (MCI) vs AD, and AUC [Formula: see text] 0.805 for the control vs MCI.

Indexed as

AgedAlzheimer DiseaseCognitive DysfunctionDisease ProgressionFemaleHippocampusHumansImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMaleNeuroimagingReproducibility of ResultsROC CurveAlzheimer’s diseaseHippocampal segmentationLongitudinal analysisMRI

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.